BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States CAMBRIDGE, Mass., ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for ...

Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the scientific ...

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across ...

Beam Therapeutics’ leukemia and lymphoma CAR-T therapy has been stopped in its tracks by the FDA after a clinical hold was placed on the new drug application. In a very brief update posted Monday ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C.

Alongside the release of abstracts related to the American Society of Hematology meeting next month in San Diego, and as part of the firm’s third-quarter update, Beam Therapeutics Inc. disclosed that ...